ROS1+ NSCLC
Oncology · 2018–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| repotrectinib Treatment of adult patients with locally advanced (Stage IIIB) or metastatic (Stage IV) c-ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer… | May 2025 | Recommended with restriction | 3 individuals Lung Foundation Australia |
| entrectinib Treatment of locally advanced (Stage IIIB) or metastatic (Stage IV) ROS1-positive non-squamous or not otherwise specified (NOS) non-small cell lung cancer… | Mar 2020 | Recommended with restriction | 6 individuals Rare Cancers Australia · Lung Foundation Australia · Medical Oncology Group |
| crizotinib Treatment of patients with locally advanced (Stage IIIB) or metastatic (Stage IV) ROS1-positive non-small cell lung cancer (NSCLC). | Jul 2018 | Recommended with restriction | 6 individuals Medical Oncology Group |
Who spoke
Medical Oncology Group · Lung Foundation Australia · Rare Cancers Australia
What the PBS pays
$6M in government benefit over 2024–25, across 907 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| entrectinib | $4.2M |
| crizotinib | $2.3M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.